Jonathan C W Edwards

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders
    J C W Edwards
    Centre for Rheumatology, University College London, Arthur Stanley House, 40 50 Tottenham Street, London W1T 4NJ, UK
    Biochem Soc Trans 30:824-8. 2002
  2. ncbi Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
    M J Leandro
    Centre for Rheumatology, University College London, UK
    Ann Rheum Dis 61:883-8. 2002
  3. ncbi Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    Jonathan C W Edwards
    University College London, London, United Kingdom
    N Engl J Med 350:2572-81. 2004
  4. ncbi B lymphocyte depletion in rheumatoid arthritis: targeting of CD20
    Jonathan C W Edwards
    Centre for Rheumatology, University College London, London, UK
    Curr Dir Autoimmun 8:175-92. 2005
  5. ncbi B-cell targeting in rheumatoid arthritis and other autoimmune diseases
    Jonathan C W Edwards
    Department of Medicine, University College London, 46 Cleveland Street, London W1P 6DB, UK
    Nat Rev Immunol 6:394-403. 2006
  6. ncbi Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis
    J C Edwards
    UCL Centre for Rheumatology, London, UK
    Arthritis Res 2:344-7. 2000
  7. ncbi B cell depletion therapy in rheumatic disease
    J C W Edwards
    University College London, Centre for Rheumatology, Arthur Stanley House, 40 50 Tottenham Street, London W1T 4NJ, UK
    Best Pract Res Clin Rheumatol 20:915-28. 2006
  8. ncbi B lymphocyte depletion therapy with rituximab in rheumatoid arthritis
    J C W Edwards
    Centre for Rheumatology, Arthur Stanley House, University College London, 40 50 Tottenham Street, London W1T 4NJ, UK
    Rheum Dis Clin North Am 30:393-403, viii. 2004
  9. ncbi A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients
    Tim Y T Lu
    University College of London, London, UK
    Arthritis Rheum 61:482-7. 2009
  10. ncbi Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab
    Inmaculada de la Torre
    Centre for Rheumatology, University College of London, London, UK
    Clin Exp Rheumatol 30:554-60. 2012

Detail Information

Publications23

  1. ncbi B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders
    J C W Edwards
    Centre for Rheumatology, University College London, Arthur Stanley House, 40 50 Tottenham Street, London W1T 4NJ, UK
    Biochem Soc Trans 30:824-8. 2002
    ....
  2. ncbi Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
    M J Leandro
    Centre for Rheumatology, University College London, UK
    Ann Rheum Dis 61:883-8. 2002
    ..These observations provide an initial basis for the design of formal trials of B cell depletion and other B cell directed treatments, including a phase II controlled trial now in progress...
  3. ncbi Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    Jonathan C W Edwards
    University College London, London, United Kingdom
    N Engl J Med 350:2572-81. 2004
    ..To confirm these observations, we conducted a randomized, double-blind, controlled study...
  4. ncbi B lymphocyte depletion in rheumatoid arthritis: targeting of CD20
    Jonathan C W Edwards
    Centre for Rheumatology, University College London, London, UK
    Curr Dir Autoimmun 8:175-92. 2005
    ..During the 1990s evidence emerged to suggest that B lymphocyte depletion in rheumatoid arthritis (RA) might be of major benefit...
  5. ncbi B-cell targeting in rheumatoid arthritis and other autoimmune diseases
    Jonathan C W Edwards
    Department of Medicine, University College London, 46 Cleveland Street, London W1P 6DB, UK
    Nat Rev Immunol 6:394-403. 2006
    ..In some subjects, the observed improvement of disease for years following therapy fuels hope that this goal might ultimately be achievable...
  6. ncbi Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis
    J C Edwards
    UCL Centre for Rheumatology, London, UK
    Arthritis Res 2:344-7. 2000
    ..These gene products contribute to specialised functions relating to tissue movement and leucocyte traffic...
  7. ncbi B cell depletion therapy in rheumatic disease
    J C W Edwards
    University College London, Centre for Rheumatology, Arthur Stanley House, 40 50 Tottenham Street, London W1T 4NJ, UK
    Best Pract Res Clin Rheumatol 20:915-28. 2006
    ..Rituximab is currently the main agent used but other agents are in development. Optimal protocols are not well characterised and will probably be different for different conditions...
  8. ncbi B lymphocyte depletion therapy with rituximab in rheumatoid arthritis
    J C W Edwards
    Centre for Rheumatology, Arthur Stanley House, University College London, 40 50 Tottenham Street, London W1T 4NJ, UK
    Rheum Dis Clin North Am 30:393-403, viii. 2004
    ....
  9. ncbi A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients
    Tim Y T Lu
    University College of London, London, UK
    Arthritis Rheum 61:482-7. 2009
    ....
  10. ncbi Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab
    Inmaculada de la Torre
    Centre for Rheumatology, University College of London, London, UK
    Clin Exp Rheumatol 30:554-60. 2012
    ..To investigate whether levels of serum immunoglobulins (sIgs) at baseline were associated with clinical parameters or B-cell dynamics following rituximab (RTX) in patients with rheumatoid arthritis (RA)...
  11. ncbi B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response
    Kristine P Ng
    Centre for Rheumatology, University College London, London, UK
    Ann Rheum Dis 66:1259-62. 2007
    ..It was also determined whether baseline parameters can predict the likelihood of disease flare...
  12. ncbi Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis
    Maria J Leandro
    University College London, Center for Rheumatology, London, UK
    Arthritis Rheum 54:613-20. 2006
    ..To study the quantitative and phenotypic reconstitution of peripheral blood B cells and its relationship to the dynamics of clinical response in patients with rheumatoid arthritis (RA) following B cell depletion with rituximab...
  13. ncbi Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse
    Geraldine Cambridge
    University College London, London, UK
    Arthritis Rheum 54:723-32. 2006
    ....
  14. ncbi Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis
    Geraldine Cambridge
    Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK
    Arthritis Rheum 48:2146-54. 2003
    ..Although these observations are consistent with a role for B lymphocytes in the pathogenesis of RA, the precise mechanisms involved remain unclear...
  15. ncbi Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics
    Inmaculada de la Torre
    Division of Rheumatology, Department of Medicine, University College London, Rayne Institute, 5 University Street, London WC1E 6JF, UK
    Rheumatology (Oxford) 51:833-40. 2012
    ..To investigate whether the incidence of secondary hypogammaglobulinaemia in patients with RA following rituximab was related to patterns of B-cell return and relapse...
  16. ncbi Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
    C Popa
    Centre for Rheumatology, University College London, Windeyer Building, Cleveland Street, London W1T 4JF, UK
    Rheumatology (Oxford) 46:626-30. 2007
    ..To assess safety and efficacy of repeated B-cell depletion with rituximab in patients with rheumatoid arthritis (RA)...
  17. ncbi Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy
    M J Leandro
    Centre for Rheumatology, University College London, London W1T 4JF, UK
    Rheumatology (Oxford) 46:29-36. 2007
    ..To assess the presence and phenotype of B-lineage cells in the bone marrow (BM) of rheumatoid arthritis (RA) patients after rituximab therapy...
  18. ncbi B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres
    Y Ioannou
    Centre for Rheumatology, Department of Medicine, University College London, 250 Euston Road, London NW1 2PG, UK
    Ann Rheum Dis 67:425-6. 2008
    ....
  19. ncbi B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response
    G Cambridge
    Centre for Rheumatology Research, Department of Medicine, 46 Cleveland St, London W1T 4JF, UK
    Ann Rheum Dis 67:1011-6. 2008
    ..To assess the relationships between serum B lymphocyte stimulator (BLyS) levels, autoantibody profile and clinical response in patients with systemic lupus erythematosus (SLE) following rituximab-based B cell depletion therapy (BCDT)...
  20. ncbi Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy
    S M Sultan
    University College London Hospital, London, UK
    Clin Exp Rheumatol 26:887-93. 2008
    ..To assess the efficacy of B lymphocyte depletion therapy (BCDT) in patients with refractive idiopathic inflammatory myopathy (IIM)...
  21. ncbi Macrophage subpopulations in rheumatoid synovium: reduced CD163 expression in CD4+ T lymphocyte-rich microenvironments
    J E Fonseca
    University College London, London, UK
    Arthritis Rheum 46:1210-6. 2002
    ..We assessed CD163 expression in microenvironments within rheumatoid arthritis (RA) synovium to clarify the relationships among CD4+ T lymphocytes, IFNgamma, and macrophage function in RA...
  22. ncbi Importance of T cells in rheumatoid synovitis: comment on the review by Firestein and Zvaifler
    Jonathan C W Edwards
    Arthritis Rheum 46:3105-6; author reply 3106. 2002
  23. ncbi Lymphoid follicles in joints: what do they mean?
    Jonathan C W Edwards
    Arthritis Rheum 58:1563-5. 2008